Thalys Medical Technology Group (SHSE:603716) Cyclically Adjusted Revenue per Share: ¥9.32 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603716 Thalys Medical Technology Group Corp SHSE:603716
43 GF Score
Price ¥17.08
GF Value ¥4.22
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Thalys Medical Technology Group Cyclically Adjusted Revenue per Share?

Thalys Medical Technology Group SHSE:603716 +4.08% 43 Cyclically Adjusted Revenue per Share is ¥9.32 as of Jun. 2026. GuruFocus rates SHSE:603716 with a GF Score™ of 43/100 and a GF Value™ of ¥4.22 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Thalys Medical Technology Group's adjusted revenue per share for the three months ended in Jun. 2026 was ¥0.746. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥9.32 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Thalys Medical Technology Group's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-29), Thalys Medical Technology Group's current stock price is ¥17.08. Thalys Medical Technology Group's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ¥9.32. Thalys Medical Technology Group's Cyclically Adjusted PS Ratio of today is 1.83.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Thalys Medical Technology Group was 3.69. The lowest was 0.57. And the median was 1.53.


Thalys Medical Technology Group  (SHSE:603716) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Thalys Medical Technology Group's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.08/9.32
=1.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Thalys Medical Technology Group was 3.69. The lowest was 0.57. And the median was 1.53.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Thalys Medical Technology Group Cyclically Adjusted Revenue per Share Related Terms


Thalys Medical Technology Group Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Thalys Medical Technology Group's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thalys Medical Technology Group Cyclically Adjusted Revenue per Share Chart

Thalys Medical Technology Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 9.49 9.39

Thalys Medical Technology Group Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.32 9.38 9.39 9.40 9.32

SHSE:603716 vs TMO, DHR, IDXX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Thalys Medical Technology Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thalys Medical Technology Group Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thalys Medical Technology Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Thalys Medical Technology Group's Cyclically Adjusted PS Ratio falls into.


SHSE:603716
43GF Score
Thalys Medical Technology Group Corp SHSE:603716
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thalys Medical Technology Group Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Thalys Medical Technology Group's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.746/116.0564*116.0564
=0.746

Current CPI (Jun. 2026) = 116.0564.

Thalys Medical Technology Group Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.728 102.400 1.958
201612 0.953 102.600 1.078
201703 1.780 103.200 2.002
201706 0.906 103.100 1.020
201709 1.442 104.100 1.608
201712 1.712 104.500 1.901
201803 1.255 105.300 1.383
201806 2.499 104.900 2.765
201809 2.633 106.600 2.867
201812 2.028 106.500 2.210
201903 1.838 107.700 1.981
201906 3.084 107.700 3.323
201909 2.309 109.800 2.441
201912 2.651 111.200 2.767
202003 1.349 112.300 1.394
202006 2.774 110.400 2.916
202009 3.077 111.700 3.197
202012 3.391 111.500 3.530
202103 3.016 112.662 3.107
202106 4.396 111.769 4.565
202109 3.064 112.215 3.169
202112 3.906 113.108 4.008
202203 2.732 114.335 2.773
202206 3.399 114.558 3.443
202209 2.443 115.339 2.458
202212 2.807 115.116 2.830
202303 2.085 115.116 2.102
202306 3.703 114.558 3.751
202309 1.949 115.339 1.961
202312 2.368 114.781 2.394
202403 3.074 115.227 3.096
202406 1.536 114.781 1.553
202409 2.221 115.785 2.226
202412 2.331 114.893 2.355
202503 1.405 115.116 1.416
202506 1.623 114.907 1.639
202509 1.317 115.471 1.324
202512 1.086 115.832 1.088
202603 0.830 116.303 0.828
202606 0.746 116.056 0.746

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥9.32 mean?
Thalys Medical Technology Group (SHSE:603716) has a Cyclically Adjusted Revenue per Share of ¥9.32 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Thalys Medical Technology Group and its competitors.
Is Thalys Medical Technology Group's Cyclically Adjusted Revenue per Share too high?
Thalys Medical Technology Group's current Cyclically Adjusted Revenue per Share is ¥9.32. Overall, Thalys Medical Technology Group has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thalys Medical Technology Group's Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Thalys Medical Technology Group's Cyclically Adjusted Revenue per Share of ¥9.32 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Thalys Medical Technology Group and its competitors. Thalys Medical Technology Group's current Cyclically Adjusted Revenue per Share is ¥9.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thalys Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Thalys Medical Technology Group (SHSE:603716) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.22, compared to a current price of ¥17.08 — trading 304.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥9.32. Thalys Medical Technology Group's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Thalys Medical Technology Group (SHSE:603716), the current Cyclically Adjusted Revenue per Share is ¥9.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thalys Medical Technology Group (SHSE:603716) Overvalued in 2026?

Based on GuruFocus' analysis, Thalys Medical Technology Group stock appears to be overvalued. The current stock price of ¥17.08 is trading 304.7% above its estimated GF Value™ of ¥4.22. GuruFocus considers Thalys Medical Technology Group to be Significantly Overvalued.

Key valuation signals for SHSE:603716:

  • Cyclically Adjusted Revenue per Share: ¥9.32
  • GF Value™: ¥4.22 vs. price of ¥17.08 (304.7% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603716 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thalys Medical Technology Group Business Description

Address 1310 Jinshan Avenue, Dongxihu District, Hubei Province, Wuhan, CHN, 430040
Thalys Medical Technology Group Corp is engaged in intensive sales business, pure sales, and research and development, production and sales of independent in vitro diagnostic products.
43GF Score

Get the complete analysis for SHSE:603716

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥17.08
Price
¥4.22
GF Value